CompletedNot Applicable

Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient

Guadeloupe92 participantsStarted 2020-10-14

Plain-language summary

Sickle cell disease is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis and chronic inflammation. Activated platelets of Sickle cell disease patients participated to both chronic inflammation and painful vaso-occlusive crisis . The main aim of this study is to characterize the contribution of Nucleotide-binding domain Leucine Rich repeat containing Protein 3 inflammasome in platelets' activation in Sickle cell disease and to connect platelet activation, inflammation and sickle cell disease complication.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with SS or SC Sickle cell disease * diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies * clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months) * patient followed up for Sickle cell disease at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre) * patients who will provide written informed consent in accordance with the Declaration of Helsinki * patients affiliated to national social security Exclusion Criteria: * \- patients with hemoglobinopathy other than SS and SC Sickle cell disease * patients with a transfusion therapy or on bleeding therapy for less than three months * patients no affiliated to national social security * pregnant or breastfeeding patients * patients who will not provide written informed consent in accordance with the Declaration of Helsinki

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

platelets' Nucleotide-binding domain Leucine Rich repeat containing Protein 3 activation

Timeframe: Baseline

Trial details

NCT IDNCT06986837

SponsorCentre Hospitalier Universitaire de la Guadeloupe

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-02-05

View on ClinicalTrials.gov More Sickle Cell Disease trials